DE69737719D1 - Substituierte gamma-aminobuttersäurederivate als arzneimittel - Google Patents

Substituierte gamma-aminobuttersäurederivate als arzneimittel

Info

Publication number
DE69737719D1
DE69737719D1 DE69737719T DE69737719T DE69737719D1 DE 69737719 D1 DE69737719 D1 DE 69737719D1 DE 69737719 T DE69737719 T DE 69737719T DE 69737719 T DE69737719 T DE 69737719T DE 69737719 D1 DE69737719 D1 DE 69737719D1
Authority
DE
Germany
Prior art keywords
pct
aminobutteric
drugs
acid derivatives
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737719T
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Christopher Horwell
Clare Octavia Kneen
David Juergen Wustrow
Andrew John Thorpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE69737719D1 publication Critical patent/DE69737719D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
DE69737719T 1996-10-23 1997-10-07 Substituierte gamma-aminobuttersäurederivate als arzneimittel Expired - Lifetime DE69737719D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2960196P 1996-10-23 1996-10-23
US5990097P 1997-09-24 1997-09-24
PCT/US1997/017997 WO1998017627A1 (en) 1996-10-23 1997-10-07 Substituted gamma aminobutyric acids as pharmaceutical agents

Publications (1)

Publication Number Publication Date
DE69737719D1 true DE69737719D1 (de) 2007-06-21

Family

ID=26705131

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737719T Expired - Lifetime DE69737719D1 (de) 1996-10-23 1997-10-07 Substituierte gamma-aminobuttersäurederivate als arzneimittel

Country Status (11)

Country Link
US (1) US6153650A (de)
EP (1) EP0937032B1 (de)
JP (1) JP2002514187A (de)
AT (1) ATE361909T1 (de)
AU (1) AU733896B2 (de)
BR (1) BR9712651A (de)
CA (1) CA2263663C (de)
DE (1) DE69737719D1 (de)
HR (1) HRP970560B1 (de)
NZ (1) NZ334898A (de)
WO (1) WO1998017627A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
TR200001794T2 (tr) * 1997-12-16 2000-10-23 Warner-Lambert Company Farmasötik maddeler olarak yeni aminler
EP0974351A3 (de) * 1998-04-24 2000-12-13 Jouveinal Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
NZ508490A (en) * 1998-07-09 2003-08-29 Warner Lambert Co Use of a combination of a GABA analog and caffeine as an analgesic
DE69934813T2 (de) * 1998-10-16 2007-10-11 Warner-Lambert Company Llc Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
WO2000031020A1 (en) * 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
FR2791982B1 (fr) * 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
CA2373210A1 (en) * 1999-05-26 2000-12-07 Warner-Lambert Company Fused polycyclic amino acids as pharmaceutical agents
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
DE60041256D1 (de) * 1999-06-10 2009-02-12 Warner Lambert Co Mono-substituierte 3-propyl-gamma-aminobuttersäure
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
EP1840117A1 (de) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- und disubstituierte 3-Propyl-gamma-aminobuttersäure
CA2320556A1 (en) * 1999-09-29 2001-03-29 Queen's University At Kingston N,n-dichlorinated omega amino acids and uses thereof
JP2003528148A (ja) * 2000-03-28 2003-09-24 デロレンゾ、ロバート・ジェイ 損傷に際して神経細胞中に形成される新規カルシウム損傷電流の阻害は神経細胞死を抑制する
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
AU2002310409C1 (en) 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (de) 2001-06-11 2004-09-29 Xenoport Inc Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
DE10203122A1 (de) * 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
IL162028A0 (en) * 2002-01-31 2005-11-20 Warner Lambert Co Alpha 2 delta ligands to treat tinnitus
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
BR0312240A (pt) * 2002-06-27 2005-04-12 Warner Lambert Co Método de tratamento do distúrbio por déficit de atenção com hiperatividade
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
AU2003286300A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
KR20050085636A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
EP1670451A4 (de) 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
US8114909B2 (en) 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
JP2007506729A (ja) 2003-09-25 2007-03-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー α２δタンパク質に親和性を有するアミノ酸のプロドラッグ
AU2004276072A1 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Amino acids with affinity for the alpha2delta-protein
NZ546381A (en) 2003-10-14 2010-01-29 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
EP1811986B1 (de) 2004-11-04 2014-03-26 XenoPort, Inc. Orale darreichungsformen von gabapentin-prodrug mit verzögerter freisetzung
MX2009006575A (es) 2006-12-22 2009-07-02 Recordati Ireland Ltd Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
CN105330603A (zh) 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
AU2014209028C1 (en) 2013-01-28 2019-08-29 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN107857710A (zh) * 2017-11-23 2018-03-30 河南师范大学 一种抗癫痫药普瑞巴林的制备方法
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1385846A (en) * 1973-05-18 1975-03-05 Le G Venny Ped I Im A I Gertse Chlorohydrate of beta-phenyl-ypsilon-amino butyric acid and process for producing same
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
ZA902661B (en) * 1989-04-10 1991-01-30 Schering Corp Mercapto-acyl amino acids
ATE117988T1 (de) * 1990-05-17 1995-02-15 Schering Corp Disulfidderivate von mercapto-acyl-aminsäuren.
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
ES2165857T3 (es) * 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
HRP970560B1 (en) 2003-02-28
HRP970560A2 (en) 1998-08-31
AU733896B2 (en) 2001-05-31
CA2263663A1 (en) 1998-04-30
WO1998017627A1 (en) 1998-04-30
NZ334898A (en) 2000-09-29
ATE361909T1 (de) 2007-06-15
US6153650A (en) 2000-11-28
JP2002514187A (ja) 2002-05-14
EP0937032B1 (de) 2007-05-09
BR9712651A (pt) 1999-10-26
CA2263663C (en) 2006-05-30
EP0937032A1 (de) 1999-08-25
AU4669797A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
DE69737719D1 (de) Substituierte gamma-aminobuttersäurederivate als arzneimittel
ATE207878T1 (de) Zyklische aminosäure als pharmazeutische wirkstoffe
ATE218135T1 (de) Zyklischaminosäure als pharmazeutische mittel
NO984204D0 (no) Nye brodannete cykliske aminosyrer som farmasöytiske midler
ATE280154T1 (de) Verzweigte alkylpyrrolidin-3-carbonsäuren
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
CA2245647A1 (en) Novel bridged cyclic amino acids as pharmaceutical agents

Legal Events

Date Code Title Description
8332 No legal effect for de